1. Weller IV, Williams IG. ABC of AIDS: antiretroviral drugs.
BMJ 322:1410–1412. 2001;
2. Knobel H, Guelar A, Montero M, et al. Risk of side effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4 cell count.
HIV Med 9:14–18. 2008;
3. Caron M, Auclairt M, Vissian A, Vigouroux C, Capeau J. Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues.
Antivir Ther 13:27–38. 2008;
4. O’Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort.
J Acquir Immune Defic Syndr 34:407–414. 2003;
5. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
N Engl J Med 354:251–260. 2006;
6. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
JAMA 292:191–201. 2004;
7. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
AIDS 21:1273–1281. 2007;
8. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity.
Am J Kidney Dis 45:804–817. 2005;
9. Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine.
Clin Infect Dis 37:e174–e176. 2003;
10. Barrios A, García-Benayas T, González-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients.
AIDS 18:960–963. 2004;
11. Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure.
Am J Med 117:282–284. 2004;
12. Peyriere H, Reyenes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases.
J Acquir Immune Defic Syndr 35:269–273. 2004;
13. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease : a case of multiple drug interactions.
Clin Infect Dis 42:283–290. 2006;
14. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity.
HIV Med 10:482–487. 2009;
15. Créput C, Gonzalez-Canali G, Hill G, et al. Renal lesions in HIV-1-positive patient treated with tenofovir.
AIDS 17:935–937. 2003;
16. Szczech LA. Renal dysfunction and tenofovir toxicity in HIV-infected patients.
Top HIV Med 16:122–126. 2008;
17. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus.
Clin Infect Dis 36:1070–1073. 2003;
18. Antoniou T, Raboud J, Chirhin S, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study.
HIV Med 6:284–290. 2005;
19. Gupta Samir K. Editorial comment: tenofovir-related nephrotoxicity: who’s at risk?
AIDS Read 17:102–103. 2007;
20. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.
Ann Intern Med 130:461–470. 1999;
21. Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules.
Lab Invest 89:513–519. 2009;
22. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
Am J Kidney Dis 57:773–780. 2011;
23. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection.
AIDS 26:867–875. 2012;
24. Rodríguez-Nóvoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.
Clin Infect Dis 48:e108–e116. 2009;
25. Mulenga L, Musonda P, Mwango A, et al. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
Clin Infect Dis 58:1473–1480. 2014;
26. Rasmussen TA, Jensen D, Tolstrup M, et al. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
PLoS One 7:e32445.2012;
27. Waheed S, Attia D, Estrella MM, et al. Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series.
Clin Kidney J 8:420–425. 2015;
28. Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome.
QJM 107:261–269. 2014;
29. Patel KK, Patel AK, Ranjan RR, Patel AR, Patel JK. Tenofovir-associated renal dysfunction in clinical practice: an observational cohort from western India.
Indian J Sex Transm Dis 31:30–34. 2010;
30. Martin M, Vanichseni S, Suntharasamai P, et al. Renal function of participants in the Bangkok tenofovir study--Thailand, 2005–2012.
Clin Infect Dis 59:716–724. 2014;
31. Jose S, Hamzah L, Campbell LJ, et al. UK Collaborative HIV Cohort Study Steering Committee. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
J Infect Dis 210:363–373. 2014;
32. Vrouenraets SM, Fux CA, Wit FW, et al. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity.
AIDS 25:2149–2155. 2011;
33. Estrella MM, Fine DM, Atta MG. Recent developments in HIV-related kidney disease.
HIV Ther 4:589–603. 2010;